Medical Technology
40 VCs and 5 funds investing in Medical Technology
VCs investing in Medical Technology
Golnaz Borghei
Principal
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Golnaz Borghei invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Olivia Doppler
ESG & Operations Associate
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Olivia Doppler supports APEX Ventures, whose published strategy is: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Anne Glover
Investment Committee Member, Amadeus APEX Technology Fund
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Anne Glover invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Hermann Hauser
Investment Committee Member, Amadeus APEX Technology Fund
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Hermann Hauser invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Tim Hos
Investment Associate
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Tim Hos invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Ion Hauer
Investment Partner
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Ion Hauer invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Bill Baumel
Managing Director
Ohio Innovation Fund
Check: $500K-$4M, as published by Ohio Innovation Fund.
Bill Baumel invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.
Michael Hughes
Venture Partner
Ohio Innovation Fund
Check: $500K-$4M, as published by Ohio Innovation Fund.
Michael Hughes invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.
Mike Triplett
Venture Partner
Ohio Innovation Fund
Check: $500K-$4M, as published by Ohio Innovation Fund.
Mike Triplett invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.
Jeff Schumann
Venture Advisor
Ohio Innovation Fund
Check: $500K-$4M, as published by Ohio Innovation Fund.
Jeff Schumann is listed in a Venture Advisor capacity at Ohio Innovation Fund. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Faith Voinovich
Principal
Ohio Innovation Fund
Check: $500K-$4M, as published by Ohio Innovation Fund.
Faith Voinovich invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.
Dave Blivin
Managing Partner
Cottonwood Technology Fund
Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.
Dave Blivin contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.
Alain le Loux
General Partner
Cottonwood Technology Fund
Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.
Alain le Loux contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.
Lee Rand
Partner
Cottonwood Technology Fund
Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.
Lee Rand contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.
Ytsen van der Meer
Principal
Cottonwood Technology Fund
Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.
Ytsen van der Meer contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.
Sabine Jansen
Corporate & Investor Relations
Cottonwood Technology Fund
Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.
Sabine Jansen contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.
Shinjan Dasgupta
Technology Analyst
Cottonwood Technology Fund
Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.
Shinjan Dasgupta contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.
Daan Boekhoudt
Investment Analyst
Cottonwood Technology Fund
Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.
Daan Boekhoudt contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.
Charles Call
SLP & Venture Partner
Cottonwood Technology Fund
Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.
Charles Call contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.
Alan Abbott
SLP & Venture Partner
Cottonwood Technology Fund
Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.
Alan Abbott contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.
Marc Subirats
General Partner
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Marc Subirats invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..
Marta G. Zanchi
Founder and Managing Partner
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Marta G. Zanchi invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..
Jordi Pedrol
Head of Finance
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Jordi Pedrol is listed in a Head of Finance capacity at Nina Capital. No person-specific investment authority is inferred; the firm's mandate is retained only as shared context.
Sebastian Anastassiou
Partner
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Sebastian Anastassiou invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..
Yahel Halamish
Partner
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Yahel Halamish invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..
Kyle Sherrill
Investment Manager
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Kyle Sherrill invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..
Fiorela Kapllanaj
Senior Analyst
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Fiorela Kapllanaj invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..
Bob Schulz
Chief Partnership Officer
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Bob Schulz is listed in a Chief Partnership Officer capacity at Nina Capital. No person-specific investment authority is inferred; the firm's mandate is retained only as shared context.
Aline Noizet
Community Manager
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Aline Noizet is listed in a Community Manager capacity at Nina Capital. No person-specific investment authority is inferred; the firm's mandate is retained only as shared context.
Guillem Torruella
Visiting Analyst
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Guillem Torruella invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..
Olivia Escudero
Visiting Analyst
Nina Capital
Check: Nina Capital does not publish one standard current check-size range on its official site.
Olivia Escudero invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..
Andreas Riegler
Founder & General Partner
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Andreas Riegler invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Wolfgang Neubert
General Partner
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Wolfgang Neubert invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Stefan Haubner
Founding Partner & General Partner
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Stefan Haubner invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Marcell Farkas
Chief Financial Officer
APEX Ventures
Check: €500K-€2.5M, as published by APEX Ventures.
Marcell Farkas supports APEX Ventures, whose published strategy is: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.
Hylton Kalvaria
Advisor
Rock Health Capital
Check: Rock Health Capital does not publish a standard current check-size range on its official site.
Hylton Kalvaria is listed in a Advisor capacity at Rock Health Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Keith W. Anderson
Advisor
Rock Health Capital
Check: Rock Health Capital does not publish a standard current check-size range on its official site.
Keith W. Anderson is listed in a Advisor capacity at Rock Health Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Monique Smith
Advisor
Rock Health Capital
Check: Rock Health Capital does not publish a standard current check-size range on its official site.
Monique Smith is listed in a Advisor capacity at Rock Health Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Bill Evans
Founder and General Partner
Rock Health Capital
Check: Rock Health Capital does not publish a standard current check-size range on its official site.
Bill Evans invests or supports investments through Rock Health Capital's published strategy: Invest in remarkable entrepreneurs working at the intersection of healthcare and technology to make healthcare massively better for every human being.
Sean Day
Principal
Rock Health Capital
Check: Rock Health Capital does not publish a standard current check-size range on its official site.
Sean Day invests or supports investments through Rock Health Capital's published strategy: Invest in remarkable entrepreneurs working at the intersection of healthcare and technology to make healthcare massively better for every human being.
Funds focused on Medical Technology
Nina Capital
Barcelona, Spain
APEX Ventures
Vienna, Austria
Cottonwood Technology Fund
Denver, Colorado / Santa Fe, New Mexico / Amsterdam and Enschede, Netherlands
Ohio Innovation Fund
Dublin, Ohio
Rock Health Capital
San Francisco, California